Videos

Amir H. Lebastchi, MD, explores the evolving landscape in the context of fusion-guided prostate biopsy methods.

“The goal of our work, essentially, was to leverage a national population-based cancer registry to comprehensively analyze multiple socioeconomic determinants of racial disparities and survival outcomes among nearly 400,000 patients with renal cell carcinoma,” says Nirmish Singla, MD, MSc.

"We had very high specificities. The specificities amongst the 3 readers ranged from 92% to 96%," says Phillip H. Kuo, MD, PhD, FACR.

“There are always other aspects of care other than that immediate treatment period that's needed,” says Samuel L. Washington III, MD.

"Overall, we found that there was a high detection rate in patients with PSA less than 1 ng/mL," says Ashesh B. Jani, MD, MSEE, FASTRO.

“In the bladder cancer field, there's been a renewed shift on looking at environmental exposures,” says Kyle A. Richards, MD, FACS.

Experts provide their perspective on the advent of third-line therapy in OAB and discuss details in the clinical process of transitioning patients out of the second-line setting.

Panelists identify key goals of therapy when treating OAB and identify resources that may aid in patient education.

Shared insight on strategies used to converse with and educate patients on pharmacologic treatment options for OAB, including the potential for adverse events tied to therapy.

"We'll have to obviously amend this document quickly as these drugs move earlier in the stage of disease," says Thomas A. Hope, MD.

"We're just trying to figure out ways to reduce our readmission rate, ways to reduce complications, and I think this is just a small step in doing that," says Randie White, MD.

“One of the things that the SMSNA does really well is promote, obviously, a lot of important learning, but also a lot of opportunities for networking,” says Matthew Ziegelmann, MD.

“We wound up finding that there was no difference in recurrence, no difference in secondary events, and no difference in our survival end points whether or not you were exposed to Agent Orange,” says Kyle A. Richards, MD, FACS.

“I think one of the most interesting things that we found is that our readmission rate was about 40%,” says Randie White, MD.

“It just gives us another piece of information that we can back up using data,” says Udit Singhal, MD.

In the second interview of the series, Paul Sieber, MD, provides expert insights on the management of adverse effects seen in patients receiving leuprolide for the treatment of advanced/metastatic prostate cancer.

Dr Amir H. Lebastchi delves into the latest advancements and evolving tactics in the field of prostate cancer biopsy and diagnostic procedures.

Amir H. Lebastchi, MD, provides insights into the current prostate cancer landscape, emphasizing the importance of prostate cancer screening and early detection.

“We wanted to look at, is there something to be said for delay in treatment or time to surgery?” says Randie White, MD.

"It's one of the hopes that our colleagues will recommend this book to their patients and their partners, so now they have a knowledgeable patient," says Neil H. Baum, MD.

Experts Naveen Kella, MD, and Dr. Shadi Esfahani, MD, MPH, consider the continued impact of PSMA PET imaging on prostate cancer management and emerging modalities that could revolutionize patient care.

"I think what should be more appropriate is that the initial treatment decision does not impact [survival], but I don't think you can say that intervening aggressively for this lethal disease does not alter the course," says Isaac Y. Kim, MD, PhD, MBA.

“The better our health care work force represents the patients we're trying to take care of, the better care we'll deliver and the better outcomes our patients will have,” says Christopher J.D. Wallis, MD, PhD.

“I think by applying these metrics that we've outlined in our manuscript, it's a perfect steppingstone in allowing urologists to take that step toward providing value-based care,” says Randall A. Lee, MD.

“I've always felt like my patients are my partners in discovery,” says Edward M. Schaeffer, MD, PhD.

“With regards to urinary function, there were actually no differences between the 2 eras. We thought that was a little surprising,” says Udit Singhal, MD.

“At this point, we really have to consider the hard work and next steps of setting up multi-institutional databases and registries aimed at drilling down on patient and provider factors and medical decision-making around this diagnosis,” says James Ferguson III, MD, PhD.

“I think the key to remember for a lot of what we're doing is that kidney stone disease is complicated. It's a really heterogenous patient population,” says Nicholas L. Kavoussi, MD.

Paul M. Yonover, MD, FACS, offers closing thoughts on unmet needs and clinical challenges surrounding the treatment of prostate cancer.

An expert on prostate cancer discusses treatment considerations for patients with high-risk prostate cancer who have high disease burden and other comorbidities.